Oncolytics Biotech Inc T.ONC

Cantor Fitzgerald Target 9$ CDN Cheers!!!

[askretka]

https://m.thefly.com/new-landing/3674665


Cantor Fitzgerald analyst Louise Chen initiated coverage of Oncolytics with an Overweight rating and C$9 price target. The potential for Oncolytics' clinical candidate, pelareorep, to boost the effectiveness of chemotherapy and a range of immunotherapies, with an immediate focus on checkpoint inhibitors, across multiple cancer indications is underappreciated, the analyst tells investors in a research note. The firm thinks pipeline advancements should drive earnings-estimate revisions and the stock higher.
Cantor Fitzgerald analyst Louise Chen initiated coverage of Oncolytics with an Overweight rating and C$9 price target. The potential for Oncolytics' clinical candidate, pelareorep, to boost the effectiveness of chemotherapy and a range of immunotherapies, with an immediate focus on checkpoint inhibitors, across multiple cancer indications is underappreciated, the analyst tells investors in a research note. The firm thinks pipeline advancements should drive earnings-estimate revisions and the stock higher.

[canadafan]

It is always good to see a new/ additional analysis on- board. the $9CDN price. seems to be in the average of where things are. all analysts have a buy rating or higher. the jones & gabl3 report is very detailed.  A few points of consensus amongst them all. 1. opportunities are there, for Pela to get to market. 2. more news to come, ASCO & other dates. 3. the SP, will b3